Intellia Therapeutics to Present at October Healthcare Investor Conferences

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced upcoming presentations at two investor conferences in October 2022. The Chardan’s 6th Annual Genetic Medicines Conference is scheduled for October 3, 2022, at 8:30 a.m. ET in a fireside chat format. The 2022 Truist Securities Genetic Medicine Summit will include a genome editing panel on October 20, 2022, at 9:00 a.m. ET. A live webcast of the Chardan presentation will be available on Intellia's website, with a replay accessible for 30 days.

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be presenting at the following upcoming investor conferences in October:

Chardan’s 6th Annual Genetic Medicines Conference, New York
Date: Monday, October 3, 2022
Time: 8:30 a.m. ET
Format: Fireside chat

2022 Truist Securities Genetic Medicine Summit, New York
Genome Editing Panel
Date: Thursday, October 20, 2022
Time: 9:00 a.m. ET
Format: Panel discussion

A live webcast of Intellia’s fireside chat at the Chardan conference will be accessible through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com. Replay of the webcast will be available on Intellia’s website for at least 30 days following the presentation.

About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatx.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com

Lina Li
Senior Director, Investor Relations and Corporate Communications
+1-857-706-1612
lina.li@intelliatx.com

FAQ

What is the date of Intellia Therapeutics' presentation at Chardan’s Genetic Medicines Conference?

Intellia Therapeutics will present at Chardan’s Genetic Medicines Conference on October 3, 2022.

What time will Intellia present at the 2022 Truist Securities Genetic Medicine Summit?

Intellia Therapeutics will present at 9:00 a.m. ET on October 20, 2022.

How can I watch the live webcast of Intellia’s fireside chat?

The live webcast of Intellia’s fireside chat can be accessed on their website during the event.

Will the webcast of the Chardan conference be available for replay?

Yes, the replay of the webcast will be available for at least 30 days after the presentation.

What technologies does Intellia Therapeutics focus on?

Intellia Therapeutics focuses on developing therapeutics leveraging CRISPR-based technologies.